We sat down with device reps and commercial leaders for the Medical Device and Pharma Growth Playbook, and the words kept changing but the story didn't. "The surgeon loved it, the eval went beautifully, and then it vanished into value analysis." "We found out there was no funded budget after three months of trial product." "Our champion walked into that committee with clinical data and got asked about total cost of care."
For a long stretch, clinical superiority plus rep access carried the day. That cover is thinner now. Access has tightened and reps reach far fewer physicians than they did a decade ago. More importantly, the decision has moved off the clinical floor. It now runs through a value-analysis committee, a GPO contract, or a procurement review you were never invited to. The clinical win and the economic decision are two different sales, and most teams are only trained to make one of them.
The damage from standing still isn't one lost account. It's spread across the territory, hidden behind a full calendar of cases and details. Trials, in-services, and field hours pour into opportunities with no funded budget. Points conceded the moment procurement pushes reset the baseline for every contract and site that follows. Sister facilities and adjacent departments get standardized by a competitor while you are covering cases down the hall. And a champion sent into committee unarmed becomes a forecast that slips a quarter, then slips again.
The fix isn't more clinical data. It's three shifts. First, qualify before you invest the eval. Is the clinical pain urgent enough to change practice? Is there funded budget, not just interest? What is the actual decision process, the committee, the procurement step, the GPO contract, and who decides against what criteria? No green light on all three means no eval. Walking away from an unfunded trial protects the inventory and the field hours you need for the account that is ready.
Second, find the economic cost beneath the clinical ask. A surgeon asks about a better device; underneath sit length of stay, complication rates, and readmission penalties the CFO is watching. A pharmacy asks about a formulary add when the real driver is total cost of care. Ask what the current approach costs the system in time, complications, and throughput, and what happens to those costs if nothing changes. Then tie your solution to the economics the committee will actually weigh, and hold your price against the benchmark rather than racing the incumbent down.
Third, arm the champion for the room you cannot enter. The most important meeting in the deal is one you will not attend. A clinician who loves the product is not automatically ready to defend it against budget questions, procurement pushback, and an incumbent contract. Give them the business case in their own language and rehearse it. Ask directly: when the committee pushes back on cost, what will you say? A thin answer is work to do before the meeting, not after.
None of this asks a rep to stop being clinically credible. It asks for one habit at a time. The team that sells only to the clinical champion is running half the sale and hoping the other half takes care of itself. The team that qualifies the full decision, builds the economic case, and rehearses it with a champion stops watching good deals die in a room they never enter.
Every eval you ran without a funded budget last quarter didn't just cost trial inventory. It cost the field hours the account that was actually ready to decide never got.
